Novocure Ltd
NVCR12.800USD
-0.020-0.16%
Cierre 10/31, 16:00（ET）Cotizaciones retrasadas 15 min
1.43BCap. mercado
PérdidaP/E TTM
Más Datos de Novocure Ltd Compañía
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Información de Novocure Ltd
Símbolo de cotizaciónNVCR
Nombre de la empresaNovocure Ltd
Fecha de salida a bolsaOct 01, 2015
Director ejecutivoMs. Ashley Cordova
Número de empleados1488
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 01
DirecciónNo. 4 The Forum
CiudadSAINT HELIER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísJersey
Código postalJE2 4UF
Teléfono441534756700
Sitio Webhttps://www.novocure.com/
Símbolo de cotizaciónNVCR
Fecha de salida a bolsaOct 01, 2015
Director ejecutivoMs. Ashley Cordova
Ejecutivos de Novocure Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
438.86K
+22.82%
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
86.17K
+30.22%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
438.86K
+22.82%
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
86.17K
+30.22%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
94.26M
59.36%
Germany
19.07M
12.01%
France
18.42M
11.60%
Other EMEA countries
12.98M
8.17%
Japan
9.48M
5.97%
Greater China
4.59M
2.89%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 2 de oct
Actualizado: jue., 2 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.96%
The Vanguard Group, Inc.
9.60%
BlackRock Institutional Trust Company, N.A.
8.04%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
6.18%
Otro
53.95%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.96%
The Vanguard Group, Inc.
9.60%
BlackRock Institutional Trust Company, N.A.
8.04%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
6.18%
Otro
53.95%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
50.51%
Hedge Fund
15.96%
Investment Advisor/Hedge Fund
15.76%
Individual Investor
10.11%
Research Firm
2.21%
Sovereign Wealth Fund
0.87%
Pension Fund
0.59%
Bank and Trust
0.31%
Venture Capital
0.12%
Otro
3.57%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
574
97.34M
87.06%
-9.98M
2025Q2
683
107.66M
96.30%
-11.23M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
16.72M
14.96%
+235.48K
+1.43%
Jun 30, 2025
The Vanguard Group, Inc.
10.73M
9.6%
-499.10K
-4.45%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.99M
8.04%
+204.02K
+2.32%
Jun 30, 2025
Wyss (Hansjorg)
8.14M
7.28%
--
--
Apr 04, 2025
Soleus Capital Management, L.P.
6.90M
6.18%
+1.38M
+25.05%
Jun 30, 2025
Capital World Investors
6.38M
5.71%
+1.17M
+22.38%
Jun 30, 2025
BlackRock Financial Management, Inc.
2.73M
2.44%
+665.88K
+32.30%
Jun 30, 2025
State Street Investment Management (US)
2.68M
2.4%
+89.36K
+3.45%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.44M
2.19%
-19.15K
-0.78%
Jun 30, 2025
Balyasny Asset Management LP
2.27M
2.03%
+634.92K
+38.83%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: lun., 6 de oct
Actualizado: lun., 6 de oct
Nombre
Proporción
SPDR S&P Health Care Equipment ETF
1.28%
Global X HealthTech ETF
1.17%
ROBO Global Healthcare Technology & Innovation ETF
1.07%
Amplify BlueStar Israel Technology ETF
0.64%
iShares Health Innovation Active ETF
0.32%
VanEck Israel ETF
0.25%
Global X Aging Population ETF
0.21%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares U.S. Medical Devices ETF
0.14%
Ver más
SPDR S&P Health Care Equipment ETF
Proporción1.28%
Global X HealthTech ETF
Proporción1.17%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.07%
Amplify BlueStar Israel Technology ETF
Proporción0.64%
iShares Health Innovation Active ETF
Proporción0.32%
VanEck Israel ETF
Proporción0.25%
Global X Aging Population ETF
Proporción0.21%
ProShares Ultra Nasdaq Biotechnology
Proporción0.14%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
iShares U.S. Medical Devices ETF
Proporción0.14%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
